Agendia, Inc.: Agendia Research Shows Highest Risk MammaPrint Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

At the 2023 ASCO® Annual Meeting, Agendia will present data that demonstrates women within MammaPrint's highest risk category have the strongest sensitivity to chemotherapy and more aggressive tumor

Related Keywords

Dallas ,Texas ,United States ,Kerry Harrington ,William Audeh ,Peter Beitsch ,Agendia Mammaprint ,Dallas Surgical Group ,Facebook ,Twitter ,Agendia Inc ,Linkedin ,Annual Meeting ,High Risk ,Ultra Low ,Chief Medical Officer ,Print Index ,Mammaprint High Risk ,Surgical Oncologist ,Dallas Surgical ,Mammaprint High ,Molecular Targets ,Clinical Oncology ,Agendia ,Research ,Shows ,Highest ,Risk ,Mammaprint ,Category ,Redicts ,Strongest ,Hemosensitivity ,Women ,Early ,Stage ,Ther2 ,Breast ,Dancer ,